REDWOOD
CITY, Calif., Jan. 29,
2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a
global medical device company that is delivering comprehensive,
life-changing solutions for the treatment of chronic pain, today
announced that the company will release its financial results for
the fourth quarter and full year ended December 31, 2023 after the market closes on
Wednesday, February 21, 2024.
The company will also host a conference call on February 21, 2024 to discuss its financial
results. The call will begin at 1:30 pm
PT / 4:30 pm ET. Investors
interested in listening to the call may do so by dialing (888)
330-2443 in the U.S. or +1 (240) 789-2728 internationally, using
conference ID: 3583097. A live webcast of this event, as well as an
archived recording, will be available in the Investors section of
Nevro's website at Events & Presentations. The live webcast
should be accessed 10 minutes prior to the conference call start
time.
About Nevro
Headquartered in Redwood City,
California, Nevro is a global medical device company focused
on delivering comprehensive, life-changing solutions that continue
to set the standard for enduring patient outcomes in chronic pain
treatment. The company started with a simple mission to help more
patients suffering from debilitating pain and developed its
proprietary 10 kHz Therapy™, an evidence-based, non-pharmacologic
innovation that has impacted the lives of more than 100,000
patients globally. Nevro's comprehensive HFX™ spinal cord
stimulation (SCS) platform includes the Senza® SCS system and
support services for the treatment of chronic pain of the trunk and
limb and painful diabetic neuropathy.
Nevro recently added a minimally invasive treatment option for
patients suffering from chronic sacroiliac joint ("SI joint") pain
and now provides the most comprehensive portfolio of products in
the SI joint fusion space, designed to meet the preferences of
physicians and varying patient needs in order to improve outcomes
and quality of life for patients.
Senza®, Senza II®, Senza
Omnia®, and HFX iQ™ are the only SCS systems that
deliver Nevro's proprietary 10 kHz Therapy™. Nevro's unique support
services provide every patient with HFX Coach™ support throughout
their pain relief journey and every physician with HFX Cloud™
insights for enhanced patient and practice management.
SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz
Therapy, HFX, the HFX logo, HFX iQ, the HFX iQ logo, HFX Algorithm,
HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo,
HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo,
RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are
trademarks or registered trademarks of Nevro Corp. Patents covering
Senza HFX iQ and other Nevro products are listed at
Nevro.com/patents.
To learn more about Nevro, connect with us on LinkedIn, X,
Facebook, and Instagram.
Investors and Media:
Angie McCabe
Vice President, Investor Relations & Corporate
Communications
angeline.mccabe@nevro.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nevro-to-report-fourth-quarter-and-full-year-2023-financial-results-and-host-conference-call-on-february-21-2024-302046818.html
SOURCE Nevro Corp.
